The company launched the product in the US following final approval from the FDA for Gedeon Richter's abbreviated new drug application.
Barr's generic version of Proscar tablets, known as finasteride tablets, are indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. The drug is designed to improve symptoms and reduce the risk of the need for surgery, including transurethral resection of the prostate and prostatectomy.
Barr's finasteride tablets will compete in a market that had total annual sales of approximately $398 million for the 12 months ending November 2006, according to IMS sales data.